- Case report
- Open Access
- Open Peer Review
Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome
© Piccoli et al; licensee BioMed Central Ltd. 2012
- Received: 18 July 2011
- Accepted: 21 February 2012
- Published: 21 February 2012
MELAS syndrome (MIM ID#540000), an acronym for Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes, is a genetically heterogeneous mitochondrial disorder with protean manifestations and occasional kidney involvement. Interest in the latter is rising due to the identification of cases with predominant kidney involvement and to the hypothesis of a link between mitochondrial DNA and kidney neoplasia.
We report the case of a 41-year-old male with full blown MELAS syndrome, with lactic acidosis and neurological impairment, affected by the "classic" 3243A > G mutation of mitochondrial DNA, with kidney cancer. After unilateral nephrectomy, he rapidly developed severe kidney functional impairment, with nephrotic proteinuria. Analysis of the kidney tissue at a distance from the two tumor lesions, sampled at the time of nephrectomy was performed in the context of normal blood pressure, recent onset of diabetes and before the appearance of proteinuria. The morphological examination revealed a widespread interstitial fibrosis with dense inflammatory infiltrate and tubular atrophy, mostly with thyroidization pattern. Vascular lesions were prominent: large vessels displayed marked intimal fibrosis and arterioles had hyaline deposits typical of hyaline arteriolosclerosis. These severe vascular lesions explained the different glomerular alterations including ischemic and obsolescent glomeruli, as is commonly observed in the so-called "benign" arteriolonephrosclerosis. Some rare glomeruli showed focal segmental glomerulosclerosis; as the patient subsequently developed nephrotic syndrome, these lesions suggest that silent ischemic changes may result in the development of focal segmental glomerulosclerosis secondary to nephron loss.
Nephron loss may trigger glomerular sclerosis, at least in some cases of MELAS-related nephropathy. Thus the incidence of kidney disease in the "survivors" of MELAS syndrome may increase as the support therapy of these patients improves.
- MELAS syndrome
- Chronic kidney disease
- Renal vascular
- Kidney cancer
MELAS syndrome (MIM ID#540000), an acronym for Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes, is a genetically heterogeneous mitochondrial disorder with protean manifestations, different expressivity and occasional kidney involvement [1–5]. The multisystem presentation, variable onset and severe cerebrovascular involvement are exemplified by the history of the philosopher and poet Friedrich Nietzsche who died at the age of 55 after a mysterious illness. Whether or not the MELAS diagnosis is true, this historical note has the merit of highlighting the variable manifestations and clinical mimicry of this rare disease .
MELAS syndrome is associated in about 80% of cases with a mutation at position 3243 in the mitochondrial gene MTTL1 (MIM ID *590050), encoding mitochondrial tRNA leucine 1(3243A > G transition), although other mutations have also been described . Interest in kidney involvement is rising due to the identification of MELAS mutations in cases with predominant kidney involvement, occasionally with very late diagnosis, and to the description of a putative link between mitochondrial DNA and different types of kidney neoplasia [8–12].
Kidney involvement is protean, and both glomerular disease (focal segmental glomerulosclerosis- FSGS) and tubular lesions, resulting in hyponatremia or in a full-blown De Toni Fanconi Debré syndrome, have been described. Furthermore, in several of the reported cases, kidney involvement was diagnosed only when advanced renal failure occurred [13–19]. The best-characterized lesion, leading to kidney biopsy in nephrotic syndrome, is FSGS. The role of early ischemic changes in the reduction of the nephron population has not yet been elucidated [13–19].
We report the case of a patient with MELAS syndrome and the "classic" 3243A > G mutation of mitochondrial DNA, who developed kidney cancer and severe and rapid kidney functional impairment after unilateral nephrectomy. Analysis of the kidney tissue at a distance from the cancer lesion, sampled in an early phase of kidney disease, in the context of normal blood pressure, recent onset of diabetes and before the appearance of proteinuria, may allow a better understanding of the pathogenesis of the renal lesions in MELAS syndrome.
A 41-year-old male was referred to our Nephrology Unit because of worsening of kidney function and proteinuria. He was born at term of a normal pregnancy from apparently healthy, nonconsanguineous parents. The patient's early development was normal and he had no evident clinical problem until 18 years of age, when he developed seizures triggered by light and recurrent headaches. He was prescribed Valproic Acid and started a discontinuous follow-up in Neurology. In 1991 (age 22) EEG revealed well-represented alpha background activity, with a complex wave-peak after 7-10 flashes/sec, an expression of an epileptogenic photosensitive centroencephalic focus. In 1992, in the presence of signs of myopathy (asthenia, increase of serum lactate, myalgia), a muscle biopsy showed non-specific changes (occasional small red sub-sarcolemmal deposits, showing oxidative enzymatic activity). In 1992 the patient's sister (3 years younger) developed generalized seizures and myopathy. Genetic counseling suggested the presence of a mitochondrial disease.
Detection of the 3243A > G mutation of mitochondrial DNA confirmed the diagnosis of MELAS syndrome in the patient, his sister, his mother and one of the mother's sisters.
In the subsequent decade, he started and discontinued different types of anticonvulsant therapy (including Lamotrigine and Phenobarbital), and developed recurrent seizures, with imaging evidence of an ischemic lesion in the left hemisphere, progressive bilateral sensorineural hearing loss and sensitive distal polyneuropathy with increasing muscle weakness. On various occasions, lactic acidosis was found (lactic acid 10-13.5 mmol/L; normal <2 mmol/L).
In July 2009 (age 39) he was diagnosed with diabetes mellitus (weight loss, polyuria and polydipsia); at diagnosis, glycated hemoglobin was 19.6% and glycemia <500 mg/dL. Insulin treatment was started. Soon after diagnosis, he developed a sepsis due to Klebsiella pneumoniae. A CT scan, performed on the suspicion of a pyelonephritis focus, showed a solid hypervascularized mass, highly suggestive of neoplasia, in the right kidney. During hospitalization, serum creatinine was 0.9 mg/dL; 24-hour proteinuria was absent at repeated urinalysis; glomerular filtration rate (eGFR) was 62 mL/min (Cockcroft and Gault formula). He was normotensive (usual blood pressure 120/80 mmHg) and remained so during follow-up.
At hospital discharge, serum creatinine was 1.17 mg/dL with mild proteinuria (30 mg/dL). In the same year the patient's sister developed breast cancer and was identified as a carrier of the BRCA-2 mutation. However, the other family members, including our patient, preferred not to perform genetic testing for the BRCA mutation.
In January 2011 the patient was referred to our center. Glycemic control was good (glycated hemoglobin 6.5% on Repaglinide). Blood pressure was normal, without therapy. Cognitive impairment and psychomotor agitation, choreiform movements and intentional tremor, nystagmus and lower limb muscle weakness, hypotrophy and severe muscle wasting were present (height 155 cm, weight 36 Kg, BMI: 15). His speech was slow, slurred but coherent, and he appeared severely depressed. His last biochemical tests were: serum creatinine 2.1 mg/dL (eGFR 23 mL/min), proteinuria 3.6 g/24 hours, low-normal total proteins (6.2 g/dL) and normal serum albumin (3.7 g/dL). EKG was normal; no sign of cardiomyopathy was detected. Further tests showed: low IgG levels (499 mg/dL), normal IgA and IgM (213 and 115 mg/dL respectively); high PTH (445 pg/mL); moderate acidosis (pH 7.227; HCO3 22.8; SBE -3.7; normal lactates: 1.2 mmol/L); antinuclear antibodies and ANCA were negative.
Renal ultrasounds showed moderate medullary hyperechogeneity, consistent with tubulo-interstitial or vascular damage.
The rapid progression of kidney disease, with the development of nephrotic proteinuria, led us to review the samples of kidney tissue at a distance from the cancer lesions.
Of note, the changes were recorded before the onset of proteinuria and in the absence of hypertension, both at nephrectomy and over the follow-up.
As the patient subsequently developed nephrotic syndrome, these lesions suggest that silent ischemic changes may result in the development of focal segmental glomerulosclerosis secondary to nephron loss, at least in some cases of MELAS-related nephropathy.
The present report regards an adult patient presenting all the clinical criteria for MELAS syndrome (stroke-like episodes, with onset before age 40; encephalopathy with seizures and cognitive impairment; mitochondrial myopathy with lactic acidosis, in the context of normal early psychomotor development and recurrent headache), as well as the most frequent complications, namely diabetes mellitus (initially defined as type 2 diabetes, but at present more often defined as mitochondrial diabetes) and sensorineural hearing loss . Molecular genetic testing identified the most common mutation found in MELAS patients, MTTL1 (MIM ID *590050), encoding mitochondrial tRNA leucine 1(3243A > G transition) [1, 20, 21].
The feature of this case is the severity and complexity of kidney involvement, characterized by kidney cancer and by severe arteriolonephrosclerosis occurring in the absence of hypertension, which we speculate may be the basis for the severe and progressive nephropathy (with the appearance of nephrotic proteinuria, previously absent) that developed shortly after nephrectomy (Figures 1 and 4).
Kidney involvement is reported to be rare and is protean in MELAS patients [1, 20]. Reported cases include: glomerular diseases, mainly FSGS; tubular disorders, either with Fanconi syndrome or in the form of salt-losing nephropathies; end-stage renal failure [2–4, 10–19, 21–23]. The presence of abnormal mitochondria in tubules and in podocytes has been described since the first reports, suggesting a direct role of mitochondrial alterations in the pathogenesis of tubular derangements and of steroid-resistant focal segmental glomerulosclerosis; unfortunately electron microscopy was not available in our case, thus impairing any conclusion on the podocyte status in our patient [12, 19]. Most cases of kidney involvement are described in adolescent and adult patients [2–4, 7, 8, 11–19]. This suggests that kidney disease may develop in the "survivors" of MELAS syndrome; if this proves to be true, its incidence may increase as the support therapy improves . To our knowledge, the role of ischemic changes, eventually resulting in the development of glomerulosclerosis secondary to nephron loss and nephrotic range proteinuria, has never been clearly described, also because these early changes may be greatly underestimated as they are typically neither symptomatic nor detected by common laboratory tests until more than 50% of the kidney parenchyma is damaged.
Our patient was normotensive and non-proteinuric at the time of nephrectomy, even if his renal function had probably started to decrease. Indeed, the assessment of glomerular filtration rate may be a challenge in MELAS syndrome: none of the commonly employed formulae for GFR assessment is precise in the presence of muscle wasting. We chose the Cockcroft and Gault formula as it takes into account the patient's weight; however, neither this nor the MDRD or EPI formulae are reliable with very low BMI (15 in our patient) and 24-hour urine studies may be biased by higher creatinine excretion due to myopathy .
The kidney tissue analysis showed a severe vascular nephropathy with ischemic damage affecting glomeruli despite the absence of hypertension (Figure 3). After nephrectomy, in parallel with the attainment of very good diabetes control, he progressively developed nephrotic proteinuria and kidney functional impairment, whose kinetics (a few months after nephrectomy) suggested an effect similar to 5/6 nephrectomy [25–27]. Thus, a non-immunologic, non-primarily metabolic but hemodynamic mechanism of increased work-load on the remnant nephrons probably contributed to the development of FSGS in our patient. Of course, the possibility of another nephropathy different from FSGS cannot be completely ruled out, although this is highly unlikely given the disease course and the genetic background.
Our data do not contrast with the reports of altered mitochondria in several kidney compartments, being analogous to what has been described in the brain, where ischemic lesions coexisted with diffuse cellular alterations and where swollen and altered mitochondria were found in different cell types, including neuronal and endothelial cells [1, 12, 19, 28–30]. The lack of steroid sensitivity of the nephrotic syndrome in MELAS patients may be due to the fact that the lesions are caused by mitochondrial alterations and by nephron loss of vascular origin [25–32].
The second interesting aspect of the kidney involvement in our patient is the presence of kidney neoplasia (Figures 2 and 3). As he refused to undergo further genetic testing, the role of the BRCA2 mutation could not be assessed. However, a relationship between kidney cancer and the BRCA2 mutation has not been reported thus far. Mitochondrial alterations have been linked to the development of cancer . While there are some reports of an association with gallbladder, colon or thyroid cancers, very few reports have linked MELAS syndrome and kidney neoplasia; an exception was a clear renal cell carcinoma in a child, a type of renal cancer quite unusual in childhood [8, 34–36]. Indeed, renal oncocytomas and chromophobe renal carcinomas, both derived from intercalated cells of the collecting duct, display morphological and functional alterations of the mitochondria [37–40]. A genetic analysis was not performed in our patient to further clarify the diagnosis; however, cromophobe carcinomas, oncocytomas and tubular oncocytosis are thought to be pathogenetically related and further definition of the lesions was not considered relevant to the case report.
Previous studies have shown that accumulation of mitochondria in renal oncocytomas is associated with somatic mutations of mitochondrial DNA, resulting in decreased activity of the respiratory chain complex , while heteroplasmic mitochondrial DNA mutations are found in chromophobe renal cell carcinomas . Therefore, it is plausible that the mitochondrial DNA mutation detected in our patient was responsible for the development of the closely related cancers [43, 44]. Moreover, oncocytoma may be the result of the intrinsic mitochondrial mutation combined with the tendency for neoplasms, including oncocytomas, to develop in chronically diseased kidneys. The occurrence of these rare and slowly progressive kidney cancers in MELAS syndrome should be kept in mind in view of the importance of nephronsparing policies in patients at risk of end-stage kidney disease because of progressive reduction of the nephron mass; due to their slow progression, their prevalence might be underestimated in patients with MELAS syndrome [37–40].
In conclusion, this case broadens the spectrum of kidney involvement in MELAS syndrome and may clarify some aspects of its pathogenesis. In particular, it shows that kidney vascular involvement may precede the development of nephrotic range proteinuria, suggesting that in some patients with MELAS syndrome the glomerular disease may be linked to the progressive reduction of the nephron mass. The association with kidney cancer suggests strict surveillance of MELAS patients for kidney neoplasia, while the rapid progression of kidney disease after nephrectomy underlines the importance of nephron-sparing policies in patients in whom renal function involvement may be "masked" by reduced muscle mass leading to "normal" creatinine values.
The patient had given informed consent for the genetic analysis of MELAS syndrome at the time of genetic counseling. He gave informed consent to the publication of the present case report and other anonymous reports on his clinical history. He did not want to perform further genetic testing for the BRCA2 mutation, as he was convinced of his poor prognosis for vascular reasons.
A copy of the written consent is available for review by the Editor-in-Chief of this journal.
To Dr Peter Christie for his careful language editing.
To the library of the San Luigi Hospital for the valuable help.
- DiMauro S, Hirano M: MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes. Gene Reviews. Edited by: Pagon RA, Bird TD, Dolan CR, Stephens K. 1993, University of Washington, Seattle, NCBI Bookshelf. PMID 20301411 (updated Oct14)Google Scholar
- Jansen JJ, Maassen JA, van der Woude FJ, Lemmink HA, van den Ouweland JM, t'Hart LM, Smeets HJ, Bruijn JA, Lemkes HH: Mutation in mitochondrial tRNA(Leu(UUR)) gene associated with progressive kidney disease. J Am Soc Nephrol. 1997, 8 (7): 1118-1124.PubMedGoogle Scholar
- Hirano M, Konishi K, Arata N, Iyori M, Saruta T, Kuramochi S, Akizuki M: Renal, complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Intern Med. 2002, 41 (2): 113-118. 10.2169/internalmedicine.41.113.View ArticlePubMedGoogle Scholar
- Lau KK, Yang SP, Haddad MN, Butani L, Makker SP: Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes syndrome with hypothyroidism and focal segmental glomerulosclerosis in a paediatric patient. Int Urol Nephrol. 2007, 39 (3): 941-946. 10.1007/s11255-006-9172-8. Epub 2007 Feb 10.View ArticlePubMedGoogle Scholar
- Koszka C: Friedrich Nietzsche (1844-1900): a classical case of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome?. J Med Biography. 2009, 17: 161-164. 10.1258/jmb.2009.009016.View ArticleGoogle Scholar
- Ringelstein EB, Kleffner I, Khulenbaumer G, Ritter MA: Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci. 2010, 299: 81-85. 10.1016/j.jns.2010.08.037.View ArticlePubMedGoogle Scholar
- Sproule DM, Kaufmann P: Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci. 2008, 1142: 133-158. 10.1196/annals.1444.011.View ArticlePubMedGoogle Scholar
- Sangkhathat S, Kusafuka T, Yoneda A, Kuroda S, Tanaka Y, Sakai N, Fukuzawa M: Renal cell carcinoma in a pediatric patient with an inherited mitochondrial mutation. Pediatr Surg Int. 2005, 21 (9): 745-748. 10.1007/s00383-005-1471-0. Epub 2005 Oct 20.View ArticlePubMedGoogle Scholar
- Bárcena C, Martínez MA, Ortega MP, Muñoz HG, Sárraga GU: Mitochondria with tubulovesicular cristae in renal oncocytomas. Ultrastruct Pathol. 2010, 34 (6): 315-320. 10.3109/01913123.2010.506021.View ArticlePubMedGoogle Scholar
- Windpessl M, Wallner M: M3243A > G: many faces of one single point mutation. Wien Klin Wochenschr. 2010, 122 (19-20): 601-10.1007/s00508-010-1458-2. author reply 601-2.View ArticlePubMedGoogle Scholar
- Lederer SR, Klopstock T, Schiffl H: MELAS: a mitochondrial disorder in an adult patient with a renal transplant. Wien Klin Wochenschr. 2010, 122: 363-365. 10.1007/s00508-010-1388-z.View ArticlePubMedGoogle Scholar
- Yanagihara C, Oyama A, Tanaka M, Nakaji K, Nishimura Y: An autopsy case of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with chronic renal failure. Intern Med. 2001, 40 (7): 662-665. 10.2169/internalmedicine.40.662.View ArticlePubMedGoogle Scholar
- Manouvrier S, Rötig A, Hannebique G, Gheerbrandt JD, Royer-Legrain G, Munnich A, Parent M, Grünfeld JP, Largilliere C, Lombes A, et al: Point mutation of the mitochondrial tRNA(Leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness. J Med Genet. 1995, 32 (8): 654-656. 10.1136/jmg.32.8.654.View ArticlePubMedPubMed CentralGoogle Scholar
- Kubota H, Tanabe Y, Takanashi J, Kohno Y: Episodic hyponatremia in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS). J Child Neurol. 2005, 20 (2): 116-120. 10.1177/08830738050200020601.View ArticlePubMedGoogle Scholar
- Nakamura S, Yoshinari M, Doi Y, Yoshizumi H, Katafuchi R, Yokomizo Y, Nishiyama K, Wakisaka M, Fujishima M: Renal complications in patients with diabetes mellitus associated with an A to G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Diabetes Res Clin Pract. 1999, 44 (3): 183-189. 10.1016/S0168-8227(99)00051-0.View ArticlePubMedGoogle Scholar
- Kurogouchi F, Oguchi T, Mawatari E, Yamaura S, Hora K, Takei M, Sekijima Y, Ikeda S, Kiyosawa K: A case of mitochondrial cytopathy with a typical point mutation for MELAS, presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Am J Nephrol. 1998, 18 (6): 551-556. 10.1159/000013406.View ArticlePubMedGoogle Scholar
- Cheong HI, Chae JH, Kim JS, Park HW, Ha IS, Hwang YS, Lee HS, Choi Y: Hereditary glomerulopathy associated with a mitochondrial tRNA(Leu) gene mutation. Pediatr Nephrol. 1999, 13 (6): 477-480. 10.1007/s004670050641.View ArticlePubMedGoogle Scholar
- Mima A, Shiota F, Matsubara T, Iehara N, Akagi T, Abe H, Nagai K, Matsuura M, Murakami T, Kishi S, Araoka T, Kishi F, Kondo N, Shigeta R, Yoshikawa K, Kita T, Doi T, Fukatsu A: An autopsy case of mitochondrial myopathy, encepalopathy, lactic acidosis and stroke-like episodes (MELAS) with intestinal bleeding in chronic renal failure. Ren fail. 2011, 33 (6): 622-625. 10.3109/0886022X.2011.585730.View ArticlePubMedGoogle Scholar
- Mochizuki H, Joh K, Kawame H, Imadachi A, Nozaki H, Ohashi T, Usui N, Eto Y, Kanetsuna Y, Aizawa S: Mitochondrial encephalomyopathies preceded by de-Toni-Debré- Fanconi syndrome or focal segmental glomerulosclerosis. Clin Nephrol. 1996, 46 (5): 347-352.PubMedGoogle Scholar
- Thambisetty M, Newman NJ: Diagnosis and management of MELAS. Expert Rev Mol Diagn. 2004, 4: 631-644. 10.1586/14737126.96.36.1991.View ArticlePubMedGoogle Scholar
- Iwasaki N, Babazono T, Tsuchiya K, Tomonaga O, Suzuki A, Togashi M, Ujihara N, Sakka Y, Yokokawa H, Ogata M, Nihei H, Iwamoto Y: Prevalence of A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA(Leu(UUR)) gene in Japanese patients with diabetes mellitus and end stage renal disease. J Hum Genet. 2001, 46 (6): 330-334. 10.1007/s100380170068.View ArticlePubMedGoogle Scholar
- Maxwell SD, Hertel A, Seibel P, Reichmann H, Bachmann G, Shachenmayr W, Hoer G, Dorndorf W: Follow-up in carriers of the 'MELAS' mutation without strokes. Eur Neurol. 1998, 39: 9-15. 10.1159/000007892.View ArticleGoogle Scholar
- Kaufman KR, Zuber N, Rueda-Lara MA, Tobia A: MELAS with recurrent partial seizures, non convulsive status epilepticus, psychosis and behavioural disturbances: case analysis with literature review. Epilepsy Behav. 2010, 18: 494-497. 10.1016/j.yebeh.2010.05.020.View ArticlePubMedGoogle Scholar
- Nguyen MT, Maynard SE, Kimmel PL: Misapplications of commonly used kidney equations: renal physiology in practice. Clin J Am Soc Nephrol. 2009, 4: 528-534. 10.2215/CJN.05731108.View ArticlePubMedPubMed CentralGoogle Scholar
- Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol. 2001, 12: 1315-1325.PubMedGoogle Scholar
- Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006, 116: 288-296. 10.1172/JCI27699.View ArticlePubMedPubMed CentralGoogle Scholar
- An WS, Kim HJ, Cho KH, Vaziri ND: Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol. 2009, 297 (4): F895-F903. 10.1152/ajprenal.00217.2009. Epub 2009 Aug 5.View ArticlePubMedGoogle Scholar
- Zhang ZQ, Niu ST, Liang XH, Jian F, Wang Y: Vascular involvement in the pathogenesis of mitochondrial encephalomyopathies. Neurol Res. 2010, 32 (4): 403-408. 10.1179/016164110X12670144526345.View ArticlePubMedGoogle Scholar
- Gilchrist JM, Sikirica M, Stopa E, Shanske S: Adult-onset MELAS. Evidence for involvement of neurons as well as cerebral vasculature in strokelike episodes. Stroke. 1996, 27 (8): 1420-1423. 10.1161/01.STR.27.8.1420.View ArticlePubMedGoogle Scholar
- Guéry B, Choukroun G, Noël LH, Clavel P, Rötig A, Lebon S, Rustin P, Bellané-Chantelot C, Mougenot B, Grünfeld JP, Chauveau D: The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol. 2003, 14 (8): 2099-2108. 10.1097/01.ASN.0000080180.51098.02.View ArticlePubMedGoogle Scholar
- Hotta O, Inoue Chiyoko N, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y: Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001, 59: 1236-1243. 10.1046/j.1523-1755.2001.0590041236.x.View ArticlePubMedGoogle Scholar
- Löwik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP: Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005, 20 (2): 336-341. 10.1093/ndt/gfh546. Epub 2004 Dec 7.ì.View ArticlePubMedGoogle Scholar
- Lu J, Sharma LK, Bai Y: Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Research. 2009, 19: 802-815. 10.1038/cr.2009.69. published online 16 June 2009.View ArticlePubMedPubMed CentralGoogle Scholar
- Abu-Amero K, Zou M, Shi Y: Mitochondrial A135149 mutation without MELAS but in association with papillary thyroid carcinoma. Clin Genet. 2004, 66 (6): 569-570. 10.1111/j.1399-0004.2004.00365.x.View ArticlePubMedGoogle Scholar
- Lorenc A, Bryk J, Golik P, Kupryjańczyk J, Ostrowski J, Pronicki M, Semczuk A, Szołkowska M, Bartnik E: Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. Mitochondrion. 2003, 3 (2): 119-124. 10.1016/S1567-7249(03)00106-5.View ArticlePubMedGoogle Scholar
- Ohno A, Mori A, Doi R, Yonenaga Y, Asano N, Uemoto S: Successful left hemihepatectomy and perioperative management of a patient with biliary cystadenocarcinoma, complicated with MELAS syndrome: report of a case. Surg Today. 2010, 40 (9): 878-882. 10.1007/s00595-009-4145-z. Epub 2010 Aug 26.View ArticlePubMedGoogle Scholar
- Trpkov K, Yilmaz A, Uzer D, Dishongh KM, Quick CM, Bismar TA, Gokden N: Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology. 2010, 57 (6): 893-906. 10.1111/j.1365-2559.2010.03726.x. 1.View ArticlePubMedGoogle Scholar
- Erlandson RA, Shek TW, Reuter VE: Diagnostic significance of mitochondria in four types of renal epithelial neoplasms: an ultrastructural study of 60 tumors. Ultrastruct Pathol. 1997, 21 (5): 409-417. 10.3109/01913129709021939.View ArticlePubMedGoogle Scholar
- Tickoo SK, Lee MW, Eble JN, Amin M, Christopherson T, Zarbo RJ, Amin MB: Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol. 2000, 24 (9): 1247-1256. 10.1097/00000478-200009000-00008.View ArticlePubMedGoogle Scholar
- Yusenko MV, Ruppert T, Kovacs G: Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci. 2010, 6 (3): 213-224.View ArticlePubMedPubMed CentralGoogle Scholar
- Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mège-Lechevallier F, Scoazec JY, Bonora E, Smeets R, Smeitink J, Lazar V, Lespinasse J, Giraud S, Godinot C, Romeo G, Simonnet H: Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet. 2008, 17 (7): 986-995.View ArticlePubMedGoogle Scholar
- Nagy A, Wilhelm M, Sükösd F, Ljungberg B, Kovacs G: Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 2002, 35 (3): 256-260. 10.1002/gcc.10118.View ArticlePubMedGoogle Scholar
- Tickoo SK, Amin MB: Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis. Am J Clin Pathol. 1998, 110: 782-787.View ArticlePubMedGoogle Scholar
- Gobbo S, Eble JN, Delahunt B, Grignon DJ, Samaratung H, Martignoni G, Zhang S, Wang M, Brunelli M, Cossu-Rocca P, Cheng L: Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical and cytogentic profiles. Am J Surg Path. 2010, 34: 620-626.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/9/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.